HUM
BEARISH
$177.86
Live
Humana Inc. · NYSE
Target $212.17
(+19.3%)
$163.11
52W Range
$315.35
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 01, 2026
Market cap
$21.45B
P/E
18.06
ROE
7.0%
Profit margin
0.9%
Debt/Equity
0.75
Dividend yield
2.04%
AI Analysis
AI-powered fundamental assessment
Confidence
65%
HUM shows bearish fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Concerns include weak profitability or high valuation.
Key Strengths
Company has established market presence
Key Risks
Low profit margin of 0.9%
Weak financial trend (Piotroski F-Score: 3/9)
AI Fair Value Estimate
Based on comprehensive analysis
$68.95
-61.2% below current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
46
Moderate
60
50
40
30
50
AI Verdict
HUM shows bearish fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Concerns include weak profitability or high valuation.
Key drivers: Company has established market presence, Low profit margin of 0.9%, Weak financial trend (Piotroski F-Score: 3/9)
Confidence
25%
Value
60/100
Rule-based valuation (P/E + Graham).
Positives
- Trades below Graham Number.
Watchpoints
No urgent risks highlighted.
Future
50/100
Rule-based growth outlook.
Positives
- Insufficient data for clear positives.
Watchpoints
No urgent risks highlighted.
Past
40/100
Historical performance + price trend: Shares moved -54.8% over 5Y and -31.8% over 1Y.
Positives
- Insufficient data for clear positives.
Watchpoints
- Thin profit margins.
Health
30/100
Balance sheet & liquidity (Z-Score: N/A).
Positives
- Insufficient data for clear positives.
Watchpoints
No urgent risks highlighted.
Dividend
50/100
Dividend policy fallback.
Positives
- Moderate dividend profile (Score: 50/100).
- Yield: 2.0%.
Watchpoints
No urgent risks highlighted.
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$177.86
Analyst Target
$212.17
Upside/Downside
+19.3%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for HUM and closest competitors.
Updated 2026-04-01
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
HUM
Humana Inc.
Primary
|
-54.8% | -63.9% | -31.8% | -27.3% | -4.6% | +2.6% |
|
CNC
Centene Corporation
Peer
|
-26.9% | -36.9% | -26.9% | +31.2% | +35.9% | +13.6% |
|
ROIV
Roivant Sciences Ltd.
Peer
|
+203.5% | +236.3% | +193.9% | +72.8% | +7.3% | +5.7% |
|
DGX
Quest Diagnostics Incorporated
Peer
|
+63.6% | +42.2% | +13.6% | +8.7% | +0.3% | +0.6% |
|
BNTX
BioNTech SE
Peer
|
-20.9% | -28.6% | -2.4% | -9.9% | -17.3% | +2.4% |
HUM
Humana Inc.
Primary
5Y
-54.8%
3Y
-63.9%
1Y
-31.8%
6M
-27.3%
1M
-4.6%
1W
+2.6%
CNC
Centene Corporation
Peer
5Y
-26.9%
3Y
-36.9%
1Y
-26.9%
6M
+31.2%
1M
+35.9%
1W
+13.6%
ROI
Roivant Sciences Ltd.
Peer
5Y
+203.5%
3Y
+236.3%
1Y
+193.9%
6M
+72.8%
1M
+7.3%
1W
+5.7%
DGX
Quest Diagnostics Incorporated
Peer
5Y
+63.6%
3Y
+42.2%
1Y
+13.6%
6M
+8.7%
1M
+0.3%
1W
+0.6%
BNT
BioNTech SE
Peer
5Y
-20.9%
3Y
-28.6%
1Y
-2.4%
6M
-9.9%
1M
-17.3%
1W
+2.4%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
18.06
Forward P/E
11.63
PEG Ratio
N/A
P/B Ratio
1.21
P/S Ratio
0.17
EV/Revenue
0.11
EV/EBITDA
4.02
Market Cap
$21.45B
Profitability
Profit margins and return metrics
Profit Margin
0.92%
Operating Margin
-1.79%
Gross Margin
14.54%
ROE
7.04%
ROA
4.3%
Growth
Revenue and earnings growth rates
Revenue Growth
+11.3%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.75
Moderate
Current Ratio
2.0
Strong
Quick Ratio
1.53
Excellent
Cash/Share
$165.04
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$32.5B
Net Margin
-2.4%
Total Assets
$48.9B
Liabilities
$31.2B
Equity
$17.7B
Debt/Equity
1.77x
Operating CF
$-1.7B
CapEx
$-0.2B
Free Cash Flow
$-1.9B
FCF Yield
112%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-04-29
$N/A
2026-02-11
$-3.96
+0.7% surprise
2025-11-05
$3.24
+14.6% surprise
2025-07-29
$6.27
+6.9% surprise
Healthcare Sector Comparison
Comparing HUM against 560 companies in the Healthcare sector
(34 bullish, 167 neutral, 359 bearish)
P/E Ratio
18.06
This Stock
vs
75.44
Sector Avg
-76.1%
(Discount)
Return on Equity (ROE)
7.04%
This Stock
vs
-88.14%
Sector Avg
-108.0%
(Below Avg)
Profit Margin
0.92%
This Stock
vs
-16.28%
Sector Avg
-105.6%
(Weaker)
Debt to Equity
0.75
This Stock
vs
2.66
Sector Avg
-71.9%
(Less Debt)
Revenue Growth
11.3%
This Stock
vs
124.04%
Sector Avg
-90.9%
(Slower)
Current Ratio
2.0
This Stock
vs
4.47
Sector Avg
-55.2%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
HUM
Humana Inc.
|
BEARISH | $21.45B | 18.06 | 7.0% | 0.9% | $177.86 | |
|
CNC
Centene Corporation
|
BEARISH | $21.39B | - | -28.7% | -3.8% | $43.5 | Compare |
|
ROIV
Roivant Sciences Ltd.
|
NEUTRAL | $21.35B | - | -19.1% | -% | $29.83 | Compare |
|
DGX
Quest Diagnostics Incorporated
|
NEUTRAL | $21.73B | 21.69 | 14.5% | 9.1% | $196.27 | Compare |
|
BNTX
BioNTech SE
|
BEARISH | $22.34B | - | -5.9% | -39.6% | $88.88 | Compare |
HUM
Humana Inc.
BEARISH
Mkt Cap
$21.4B
P/E
18.1
ROE
7.0%
Price
$177.86
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-24 | VENTURA JOSEPH CHRISTOPHER | Officer | Stock Award | 1,035 | - |
| 2026-02-24 | FELTER JOHN- PAUL W. | Officer | Stock Award | 165 | - |
| 2026-02-24 | RENAUDIN GEORGE II | Officer | Stock Award | 1,035 | - |
| 2026-02-23 | SHETTY SANJAY K | Officer | Purchase | 810 | $150,016 |
| 2026-02-23 | FELTER JOHN- PAUL W. | Officer | Stock Award | 5,669 | - |
| 2026-02-20 | DINTENFASS DAVID | Officer | Stock Award | 3,858 | - |
| 2026-02-13 | MEHTA JAPAN | Chief Technology Officer | Stock Award | 1,682 | - |
| 2026-02-13 | MELLET CELESTE | Chief Financial Officer | Stock Award | 7,763 | - |
| 2026-02-12 | MARTIN AARON | Officer | Stock Award | 17,031 | - |
| 2026-01-08 | RECHTIN JAMES A. | Chief Executive Officer | Stock Award | 2,183 | - |
| 2026-01-02 | FEINBERG DAVID T | Director | Stock Award | 766 | - |
| 2026-01-02 | MESQUITA JORGE S | Director | Stock Award | 766 | - |
| 2025-12-31 | O'HARA MICHELLE A. | Officer | Stock Award | 2,353 | - |
| 2025-12-15 | VENTURA JOSEPH CHRISTOPHER | Officer | Stock Award | 2,406 | - |
| 2025-12-15 | O'HARA MICHELLE A. | Officer | Stock Award | 1,401 | - |
VENTURA JOSEPH CHRISTOPHER
Officer
2026-02-24
1,035 shares
FELTER JOHN- PAUL W.
Officer
2026-02-24
165 shares
RENAUDIN GEORGE II
Officer
2026-02-24
1,035 shares
SHETTY SANJAY K
Officer
2026-02-23
810 shares
·
$150,016
FELTER JOHN- PAUL W.
Officer
2026-02-23
5,669 shares
DINTENFASS DAVID
Officer
2026-02-20
3,858 shares
MEHTA JAPAN
Chief Technology Officer
2026-02-13
1,682 shares
MELLET CELESTE
Chief Financial Officer
2026-02-13
7,763 shares
MARTIN AARON
Officer
2026-02-12
17,031 shares
RECHTIN JAMES A.
Chief Executive Officer
2026-01-08
2,183 shares
FEINBERG DAVID T
Director
2026-01-02
766 shares
MESQUITA JORGE S
Director
2026-01-02
766 shares
O'HARA MICHELLE A.
Officer
2025-12-31
2,353 shares
VENTURA JOSEPH CHRISTOPHER
Officer
2025-12-15
2,406 shares
O'HARA MICHELLE A.
Officer
2025-12-15
1,401 shares
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
NONE
24 analysts
Barclays
2026-02-25
Equal-Weight
Equal-Weight
Wells Fargo
2026-02-18
Equal-Weight
Equal-Weight
Goldman Sachs
2026-02-17
Sell
Sell
Truist Securities
2026-02-17
Hold
Hold
TD Cowen
2026-02-13
Hold
Hold
Jefferies
2026-02-12
Buy
Buy
UBS
2026-02-12
Neutral
Neutral
RBC Capital
2026-02-12
Outperform
Sector Perform
Guggenheim
2026-02-12
Buy
Buy
Cantor Fitzgerald
2026-02-12
Neutral
Neutral
Past News Coverage
Recent headlines mentioning HUM from our newsroom.
Newest → oldest
No matching news yet.